|
ISIS Report 31/03/06
Therapeutic Vaccines for Allergy in GM Rice
Known to cause asthma in clinical trials. Prof.
Joe Cummins
The immune system has learned to distinguish between
self and non-self. The cells lining the digestive system or airways encounter
antigens in food and numerous non-pathogenic
bacteria. To cope with food or bacteria that are not harmful, the immune system
develops oral tolerance. Repeated exposure to antigens in food or harmless
bacteria leads to a state of oral
tolerance in which the antigen is recognized as self and does not provoke
an immune response [1].
Allergic
and autoimmune diseases are forms of immune hypersensitivity that increasingly cause ill
health. Most current therapies for the diseases treat symptoms rather then
the underlying causes. The pathologically hypersensitive can be desensitized
using vaccines consisting of synthetic peptides representing ‘T cell epitopes’,
the portion of the antigens provoking the immune response [2]. T cells are
the key mediators of specific immune responses against infectious diseases
or cancer, and are also involved in allergies. A crucial event in T cell activation
is the presentation of peptides derived from protein antigens.
This event is accomplished by the intracellular fragmentation of specific
protein antigens, followed by the binding
of the resultant peptide epitopes to HLA (Human Leukocyte Antigen) molecules
and presented on the cell surface of antigen presenting cells (APCs) for recognition
by specific T-cell receptors.
|
Global warming is accelerating and energy prices are soaring. We have to find the right survival strategies, and we have to find them now. Time and energy resources are both running out; squander them on the wrong technologies and the consequences will be catastrophic, invest in the right options and we can mitigate climate change and thrive in a post fossil fuel world.
This report will help you make the right choices
among nuclear, biofuels, wind, solar, energy from wastes, and more…
Send it to your policy-makers to input to the global energy debate. Sponsor this report by making a donation that will entitle you to multiple copies at print price plus p&p. For details please e-mail: energy@i-sis.org.uk
Hard copies and an electronic version are available at the ISIS online store
|
|
|
Synthetic T-cell
epitopes derived from the primary sequence of allergen molecules are used
to down regulate allergic inflammation in sensitized individuals in a manner
similar to oral tolerance. The approach has a substantial advantage over treatment
with entire allergen molecules, which often persist in activating the cells
involved in allergic inflammation
[3]. The therapeutic peptide epitopes are ingested, delivered through airways
or injected into the bloodstream. Clinical trials of T cell epitope peptides
using injection proved equivocal; a number of studies found that the peptides
actually induced an asthmatic response [4].
GM rice was
developed to treat allergy. This development may lead to an avalanche of GM pharm crops to fight allergies such as cat,
dust mites, nuts, etc. The T cell epitopes for the Japanese
cedar pollen allergy peptide are used to create oral tolerance (oral intake
of allergens to create tolerance by causing the immune system to regard the
allergen as food and thus safe). The epitope peptides are selected, cutting
out the parts of the original protein triggering the allergy response, sneezing,
coughing , etc). Inducing oral tolerance relieves the allergic response to
cedar pollen. Introducing the T- cell epitopes into rice is achieved by introducing
the gene segment specifying the epitope causing the allergy in humans fused
to the soybean seed storage protein glycinin into the rice genome so that
a rice meal should prevent the allergic response to cedar pollen. The epitope
gene was driven by a rice glutelin promoter, followed by a glutelin signal
peptide sequence, a rice endoplasmic retention signal and a transcription
termination gene from rice glutelin.
The gene insert cassette also included a hygromycin antibiotic resistance
gene driven by a CaMV promoter and transcription was terminated by a agropine
sequence [5, 6]. Sneezing transgenic mice exposed to the allergen were relieved
of allergy symptoms and the accompanying serum allergen IgE and IgG antibodies
and CD4+ proliferation response [6].
The
use of rice to treat allergy has the potential to pollute the rice food crop
with genes causing allergy in humans and an antibiotic resistance gene. The
report also did not consider detrimental side-effects of the epitope peptides,
for example the asthma reported in humans during clinical trials. However,
there is little doubt that the use of human T
cell epitope peptides produced in crop plants to treat a wide array of allergies
and autoimmune diseases is going
to be a major focus in the very near future. These developments may well exacerbate
the current “major epidemic” of asthma if unchecked.
Please
send this paper to your policy-makers and demand strict regulation, risk assessment
and safety studies on these crops.
References
- Mayer L. and Shao L. Therapeutic potential of oral
tolerance. Nature Rev. Immunol.
2004, 4, 407-19.
- Larche M. and Wraith D. Peptide-based therapeutic
vaccines for allergenic and autoimmune diseases. Nature Medicine supplement 2005, 11,
S69-S76.
- Verhoef A, Alexander C, Kay A. and Larche M. T cell
immunotherapy induces a CD4 T cell population with regulatory activity.
PLOS Medicine 2005, 2, 0253-0261.
- Linhart B. and Valenta R. Molecular design of allergy
vaccines. 2005, current opinion in immunology 17,1-10.
- Takagi H, Saito S, Yang L, Nagasaka S, Nishizawa
N and Takaiwa F. Oral immunotherapy against a pollen allergy using a seed
based peptide vaccine. Plant Biotechnology
Journal 2005, 3, 521-33.
- Takagi H, Hiroi T, Yang L, Tada Y, Yuki Y, Takamura
K, Ishimitsu R, Kawauchi H, Kiyono H, and Takaiwa F. 2005 A rice-based edible
vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition
of Th2-mediated IgE responses.. Proc. Natl Acad. Sci. USA. 2005 doi/10.1073/pnas.0503428102
(early edition Nov. 8)
| |
|